Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Culture, Organoids & Organ-on-a-Chip Europe 2021

Roger Kamm's Biography



Roger Kamm, Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering, Massachusetts Institute of Technology (MIT)

Kamm is currently the Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering at MIT, where he has served on the faculty since 1978. Kamm has long been instrumental in developing research activities at the interface of biology and mechanics, formerly in cell and molecular mechanics, and now in engineered living systems. Current interests are in developing models of healthy and diseased organ function using microfluidic technologies, with a focus on vascularization. Kamm has fostered biomechanics as Chair of the US National Committee on Biomechanics (2006-2009) and of the World Council on Biomechanics (2006-2010). Kamm currently directs the NSF Science and Technology Center on Emergent Behaviors of Integrated Cellular Systems. He is the 2010 recipient of the ASME Lissner Medal (American Society of Mechanical Engineering) and the 2015 recipient of the Huiskes Medal (European Society of Biomechanics), both for lifetime achievements, and is the inaugural recipient of the ASME Nerem Medal for mentoring and education. He was elected to the National Academy of Medicine in 2010. Kamm is co-founder of two companies, Cardiovascular Technologies and AIM Biotech, a manufacturer of microfluidic systems for 3D culture.

Roger Kamm Image

Organ-specific Models of Barrier Function

Tuesday, 29 June 2021 at 17:00

Add to Calendar ▼2021-06-29 17:00:002021-06-29 18:00:00Europe/LondonOrgan-specific Models of Barrier Function3D-Culture, Organoids and Organ-on-a-Chip Europe 2021 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Barrier function, the ability to selectively allow passage of molecules or nanoparticles based on their physicochemical properties, is critical in numerous physiological and pathological settings. Here we discuss two examples.  The first is transport across the blood-brain barrier of therapeutic molecules or nanoparticles.  Focusing on the exchange of proteins of varying size and functionalized nanoparticles for targeting cytotoxic agents to glioblastoma multiform the mechanisms and control of delivery will be discussed.  The second model involves subcutaneous delivery of monoclonal antibodies and their bioavailability.  Brain and skin models are all human-derived and utilize either primary cells or iPSC-derived cells. Studies are based on a common microfluidic platform in which vascular networks (both blood and lymphatic) are grown by self-assembly within a 3D matrix.  Flows and pressures are controlled via simple onboard pumping systems capable of continuous circulation of a small volume of medium at physiological flow rates, with or without circulating immune cells.  These systems are compatible with moderate throughput studies in a standard 96-well format.


Add to Calendar ▼2021-06-28 00:00:002021-06-30 00:00:00Europe/London3D-Culture, Organoids and Organ-on-a-Chip Europe 20213D-Culture, Organoids and Organ-on-a-Chip Europe 2021 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com